Lv1
60 积分 2025-09-03 加入
An evaluation of sugemalimab for the treatment of relapsed or refractory extranodal natural killer T-cell lymphoma
1个月前
已完结
PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase
1个月前
已完结
From infection to immune exhaustion: The Epstein-Barr virus and its contribution to Immunosenescence
2个月前
已完结
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
2个月前
已完结
Encouraging prospects with sugemalimab in relapsed or refractory extranodal natural killer/T-cell lymphoma
3个月前
已完结
Phase 2 Study of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-Hodgkin Lymphomas
3个月前
已关闭
Camrelizumab for relapsed or refractory classical Hodgkin lymphoma: Extended follow‐up of the multicenter, single‐arm, Phase 2 study
5个月前
已完结
Emerging therapeutic strategies for mature T-cell and natural killer-cell lymphomas
5个月前
已完结
Advancing understanding of mature T-cell and natural killer-cell lymphomas
5个月前
已完结
Extranodal NK/T-cell lymphoma: an update of the molecular characterization of the tumor and microenvironment, and its clinical implications
5个月前
已关闭
皖公网安备34019202002308